Nemocnice AGEL Ostrava-Vitkovice a.s.
- Address
- lock Available on a paid plan
Neoplasms
The department focuses on malignant lung tumors, primarily Non‑Small Cell Lung Cancer. It also studies Small Cell Lung Cancer. Ongoing trials evaluate novel targeted therapies such as EGFR, KRAS and HER2 inhibitors, and combine them with immunotherapy to improve disease‑free and overall survival.
- Combination of EGFR or KRAS inhibitors with chemotherapy
- Adjuvant pembrolizumab after surgical resection
- Selpercatinib for RET‑fusion positive disease
- Dual checkpoint blockade in limited‑stage small‑cell lung cancer
- Dose‑optimization studies of novel agents in KRAS‑mutant tumors
Nemocnice AGEL Ostrava‑Vitkovice a.s. is running 20 clinical trials with six investigators, reflecting a robust thoracic oncology program.
Respiratory Tract Diseases
Research at the site covers a wide range of lung conditions, with a strong emphasis on advanced carcinoma. Trials aim to assess new systemic regimens and post‑surgical strategies that can lower recurrence rates and extend patient survival.
- Adjuvant V940 plus pembrolizumab in resected stage II‑IIIA disease
- MK‑2870 combined with pembrolizumab versus pembrolizumab alone
- Tarlatamab plus durvalumab versus durvalumab monotherapy in extensive‑stage SCLC
- Olomorasib (LY3537982) with standard of care for KRAS‑G12C mutant NSCLC
- Comparison of ensartinib versus crizotinib in ALK‑positive NSCLC
The multidisciplinary team integrates pulmonology and oncology expertise, supporting patient enrollment across the Czech Republic.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 60 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Merck Sharp & Dohme LLC4active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC6trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice AGEL Ostrava-Vitkovice a.s.
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke | Shionogi B.V. | Phase II | Not Yet Recruiting | Feb 2024 | Jun 2026 |
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 11 | Unknown | 2020-09-29 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.